About Satellos
We ask different questions, follow the science wherever it leads, and move fast — because patients don’t have time to wait.
pathways for medicines
Satellos was founded on a simple but powerful idea: In Duchenne muscular dystrophy, the real problem isn’t just muscle damage. It’s that the body can’t repair it.
Our research revealed that dystrophin does more than protect muscle fibers — it plays a key role in signaling muscle stem cells to divide. Without that signal, the body can’t keep up with the muscle it’s losing. Over time, repair falters.
We’re developing a small molecule approach to help restore that process — by targeting a biological pathway that may replace the missing dystrophin signal. It’s a different way of thinking about Duchenne. And it’s guiding us toward a new approach to treating degenerative muscle diseases.
Leadership
We’re a team of scientists, drug developers, and industry experts with deep experience in rare disease, stem cell biology, small molecule therapeutics and drug development.
What brings us together is a shared belief: that the key to treating degenerative muscle diseases lies in restoring the body’s natural ability to repair itself.
From our founding insight in muscle stem cell biology to our current clinical program in Duchenne, we’re fueled by a passion to turn that belief into something real for people living with muscle diseases.
Senior Leadership
Board of Directors